Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles

Claudio Vernieri, Michele Prisciandaro, Monica Milano, Maria Silvia Cona, Claudia Maggi, Marta Brambilla, Alessia Mennitto, Chiara Fabbroni, Elena Farè, Sara Cresta, Luigi Celio, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud

Research output: Contribution to journalArticle

Abstract

Gemcitabine or carboplatin-gemcitabine (CG) are commonly used in the treatment of advanced breast cancer. We retrospectively compared the efficacy and safety of these treatment regimens in a heterogeneous patient population. Despite a trend toward a higher rate of objective responses, CG was associated with more frequent adverse events and no evidence of better progression-free survival compared to single-agent gemcitabine.

Original languageEnglish
Pages (from-to)e306-e318
JournalClinical Breast Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Adverse events
  • Metastatic breast cancer
  • Objective response rate
  • Overall survival
  • Progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles'. Together they form a unique fingerprint.

  • Cite this